India, June 8 -- CorMedix Therapeutics (CRMD) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling in favor of its subsidiary Melinta Therapeutics, upholding the validity of patents covering MINOCIN for Injection and confirming infringement by Nexus Pharmaceuticals proposed generic product.
The decision follows a four-day bench trial in 2023, where the U.S. District Court for the Northern District of Illinois found in favor of CorMedix on all patent infringement and validity issues. The Federal Circuit also upheld a permanent injunction preventing Nexus from marketing its generic minocycline product until patent expiration.
MINOCIN is a tetracycline-derived antibiotic used primarily in hospital and ...